<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/rhythm-pharmaceuticals-inc-logo-1200x675.jpg/query-dj0yMDIyMTEyOTE2NTUxMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/rhythm-pharmaceuticals-inc-logo-1200x675.jpg/query-dj0yMDIyMTEyOTE2NTUxMg"/>Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) insider Pamela Cramer sold 3,350 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the transaction, the insider owned 20,814 shares of the company's stock, valued at approximately $2,310,354. This trade represents a 13.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.</p><h2>Rhythm Pharmaceuticals Stock Performance</h2><ul><li>7 Stocks That Will Drive the Weight Loss Drugs Market</li></ul><p>NASDAQ RYTM opened at $112.52 on Tuesday. The business's 50 day moving average price is $105.60 and its 200-day moving average price is $92.84. Rhythm Pharmaceuticals, Inc. has a fifty-two week low of $45.90 and a fifty-two week high of $122.20. The company has a market cap of $7.51 billion, a P/E ratio of -36.30 and a beta of 1.96. </p><p>Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.10). The company had revenue of $51.30 million during the quarter, compared to the consensus estimate of $50.71 million. Rhythm Pharmaceuticals had a negative return on equity of 433.21% and a negative net margin of 110.32%. As a group, equities analysts predict that  Rhythm Pharmaceuticals, Inc. will post -4.32 EPS for the current year. </p><h2>Wall Street Analyst Weigh In</h2><hr/><hr/><br/><ul><li> 2 biotechs with promising weight-loss drugs coming</li></ul><p>RYTM has been the subject of a number of recent analyst reports. JMP Securities lifted their price target on shares of Rhythm Pharmaceuticals from $135.00 to $142.00 and gave the stock a &#34;market outperform&#34; rating in a research note on Thursday, September 25th. Morgan Stanley  reiterated an &#34;overweight&#34; rating and issued a $150.00 price target on shares of Rhythm Pharmaceuticals in a report on Thursday. Oppenheimer downgraded Rhythm Pharmaceuticals from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Wednesday, November 5th. Needham &amp; Company LLC lifted their target price on Rhythm Pharmaceuticals from $120.00 to $145.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, December 11th. Finally, Cowen  restated a &#34;buy&#34; rating on shares of Rhythm Pharmaceuticals in a report on Thursday. One investment analyst  has rated the stock with a Strong Buy rating, fifteen have issued  a Buy rating, one  has assigned  a Hold rating and one  has assigned  a Sell rating to the company. According to MarketBeat, Rhythm Pharmaceuticals  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $124.27.</p><p><b>View Our Latest Stock Analysis on RYTM</b></p><h2>Hedge Funds Weigh In On Rhythm Pharmaceuticals</h2><p>A number of hedge funds and other institutional investors have recently made changes to their positions in RYTM. PNC Financial Services Group Inc. raised its holdings in shares of  Rhythm Pharmaceuticals by 1,386.2% in the first quarter. PNC Financial Services Group Inc. now owns 4,518 shares of the company's stock valued at $239,000 after acquiring an additional 4,214 shares in the last quarter.  Charles Schwab Investment Management Inc. raised its holdings in shares of  Rhythm Pharmaceuticals by 1.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 445,429 shares of the company's stock valued at $23,594,000 after purchasing an additional 5,179 shares in the last quarter.  Nuveen LLC purchased a new stake in shares of  Rhythm Pharmaceuticals in the 1st quarter worth approximately $7,803,000.  Russell Investments Group Ltd. boosted its stake in shares of  Rhythm Pharmaceuticals by 11,412.3% during the first quarter. Russell Investments Group Ltd. now owns 114,778 shares of the company's stock valued at $6,080,000 after purchasing an additional 113,781 shares in the last quarter.  Finally, Aberdeen Group plc boosted its stake in shares of  Rhythm Pharmaceuticals by 34.3% during the first quarter. Aberdeen Group plc now owns 108,129 shares of the company's stock valued at $5,728,000 after purchasing an additional 27,612 shares in the last quarter. </p><h2>Rhythm Pharmaceuticals Company Profile</h2><p> (Get Free Report)</p><p>Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.</p><h2>See Also</h2><ul><li>Five stocks we like better than Rhythm Pharmaceuticals</li><li>3 Tickers Leading a Meme Stock Revival</li><li>ServiceNow’s $7 Billion Gamble: Panic or Opportunity?</li><li>Low PE Growth Stocks: Unlocking Investment Opportunities</li><li>Dell and HP Are Raising Prices—And Investors Should Take Note</li><li>How to Know Which Cryptocurrency to Buy: A Guide for Investors</li><li>Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at Rhythm Pharmaceuticals?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Rhythm Pharmaceuticals and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://nlimgs.sfo2.cdn.digitaloceanspaces.com/2024/emailimgs/sadeduct.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="797" height="417" original-src="https://imageproxy.pbkrs.com/https://nlimgs.sfo2.cdn.digitaloceanspaces.com/2024/emailimgs/sadeduct.png"/></p><div><p>Can Any Expenses Be Deducted From Capital Gains Tax?</p><p>If you've built substantial wealth, capital gains taxes may quietly erode far more of your investment returns ...</p><p><span>SmartAsset</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjYyMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjYyMw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251202165042_pushainewer-1.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251202165042_pushainewer-1.jpg"/></p><div><p>Do you know what Amazon is planning for January 1?</p><p>Why Silicon Valley &amp; President Trump Are Backing This New Breakthrough  It's not artificial intelligence, cr...</p><p><span>Stansberry Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjUyOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjUyOA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251008163638_pushgold-bullion-163553640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251008163638_pushgold-bullion-163553640.jpg"/></p><div><p>First Time Since 2007: All Warnings Active</p><p>A free report revealing the 7 key indicators that have predicted every major economic collapse since 1929.  ...</p><p><span>American Alternative</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQ4OQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQ4OQ"/></p></div></div><div><p></p><div><p>$4,200 gold is nice ... but here’s what most gold bugs are missing</p><p>Gold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...</p><p><span>Weiss Ratings</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjMxMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjMxMg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20251014140916_unnamed.png/query-MTc2MDQ2ODk1OTIxOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="512" height="288" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20251014140916_unnamed.png/query-MTc2MDQ2ODk1OTIxOA"/></p><div><p>End of America update</p><p>There are five truths reshaping America’s financial future — and ignoring them could be costly. From an overex...</p><p><span>Porter &amp; Company</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjUxMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjUxMg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251013195604_pushtrumpnew-3.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251013195604_pushtrumpnew-3.jpg"/></p><div><p>NEW LAW: Congress Approves Setup For Digital Dollar?</p><p>Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0  But according to Rep. Marjorie Taylor ...</p><p><span>Goldco Precious Metals</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQ2Nw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQ2Nw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250918085124_pushelon-musk-7628216640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250918085124_pushelon-musk-7628216640.jpg"/></p><div><p>Elon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)</p><p>DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...</p><p><span>Angel Publishing</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQyOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQyOA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2052push_trump_new-5.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2052push_trump_new-5.jpg"/></p><div><p>Altucher: It Looks Like My Trump prediction is coming true</p><p>New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...</p><p><span>Paradigm Press</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQxMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQxMg"/></p></div></div></div>                     </div>                 </div></div>

RYTM

<p>Pamela Cramer, an insider at Rhythm Pharmaceuticals, sold 3,350 shares at $111 each, totaling $371,850. This sale reduced her ownership by 13.86%, leaving her with 20,814 shares valued at $2,310,354. The transaction was disclosed in an SEC filing. Rhythm Pharmaceuticals' stock performance and analyst ratings were also discussed, with a consensus rating of 'Moderate Buy' and a price target of $124.27.</p>

Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Pamela Cramer Sells 3,350 Shares